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Cannabinoid receptors (CB1 and CB2) are 
ubiquitous within the brain (Wilson and 
Nicoll, 2002; Eggan and Lewis, 2007). Their 
distribution and role in the modulation of dif-
ferent neurotransmitter systems (Pertwee and 
Ross, 2002; Pertwee, 2008a) clearly indicate 
that cannabinoids are involved in the modu-
lation of different cognitive and emotional 
processes (Solowij and Michie, 2007). The 
role of the endocannabinoid system in this 
has attracted the attention of basic scientists 
for decades (Zanettini et al., 2011). The modu-
lation of cognitive and emotional processes 
in man by the extracts of Cannabis sativa 
(C sativa), the most commonly used illicit 
drug consumed by an estimated 4% of the 
adult population worldwide (Copeland and 
Swift, 2009), has also been known for a long 
time and extensively investigated in experi-
mental and observational studies (Solowij, 
1998; Ranganathan and D’Souza, 2006; 
Solowij and Michie, 2007; Crippa et al., 2009; 
D’Souza et al., 2009). However, only over the 
last 20 years has it been possible to precisely 
investigate the neural basis of the acute effects 
of cannabinoids on cognition by employ-
ing sophisticated neuroimaging techniques 
(Bhattacharyya et al., 2009a, 2012a; Martin-
Santos et al., 2010). A renewed interest in the 
link between regular cannabis use and devel-
opment of psychotic disorders has provided 
further impetus, coupled with interest in the 
therapeutic potential of certain cannabinoids.
Pharmacological challenge studies 
involving the administration of cannabi-
noids present in the extract of C sativa or 
their synthetic counterparts in combination 
with neuroimaging have served to comple-
ment current understanding regarding 
the role of the endocannabinoid system in 
regulating human cognitive and emotional 
processes (Zanettini et al., 2011), to model 
aspects of various psychiatric illnesses in 
man and understand their neural underpin-
nings (Bhattacharyya et al., 2009a). Among 
the more than 60 different cannabinoids 
(Mechoulam and Gaoni, 1967) present in the 
extract of C sativa, delta-9-tetrahydrocanab-
inol (THC) is thought to be responsible for 
most of the psychotropic effects of cannabis 
(Mechoulam et al., 1970) and modulation 
of cognitive domains such as learning and 
memory (Hall and Solowij, 1998; Curran 
et al., 2002; Ranganathan and D’Souza, 
2006), psychomotor control (Hart et al., 
2001; McDonald et al., 2003; Ramaekers 
et al., 2006, 2009), and attention (Hall and 
Solowij, 1998; Ilan et al., 2004), as evident 
from systematic acute experimental studies. 
The purpose of this article is to provide a 
brief critical overview of current neuroimag-
ing evidence of the acute effects of THC in 
man as evident from neuroimaging studies. 
The studies are organized into groups based 
on neuroimaging domains examined.
MeMory and verbal learning
To date, three functional magnetic resonance 
imaging (fMRI) studies have examined the 
neural correlates of the effects of cannabi-
noids on memory processing, the only cog-
nitive domain robustly affected in chronic 
cannabis users and following acute admin-
istration (Grant et al., 2003; Ranganathan 
and D’Souza, 2006; Solowij and Michie, 
2007; D’Souza et al., 2008). Bhattacharyya 
et al. (2009b) examined the effects of THC 
on neural activation while healthy occa-
sional cannabis users performed a learning 
task that involved the repeated presentation 
of verbal stimuli. Consistent with previ-
ous reports (Zeineh et al., 2003), most of 
the learning under the placebo condition 
occurred during the first presentation of 
the encoding block and there was a linear 
decrement in the engagement of the para-
hippocampal gyrus, which is involved in the 
encoding of contextual information about 
stimuli that may be reactivated later to aid 
in recollection (Eichenbaum et al., 2007). 
Administration of THC disrupted the normal 
linear decrement present with placebo in the 
engagement of the parahippocampal cortex, 
which is involved in the encoding of contex-
tual information about stimuli (Eichenbaum 
et al., 2007). Furthermore, the relationship 
between the change in parahippocampal 
activation and memory performance pre-
sent with placebo was disrupted by THC, 
consistent with evidence that THC impairs 
medial temporal function in animals (Robbe 
et al., 2006; Puighermanal et al., 2009; Wise 
et al., 2009) and memory performance in ani-
mals and man (Curran et al., 2002; D’Souza 
et al., 2004; Robbe et al., 2006; Puighermanal 
et al., 2009; Wise et al., 2009). These results 
may reflect increased demands on encoding 
under the influence of THC as a result of an 
impairment in the efficient encoding of con-
textual information in the medial temporal 
cortex, which has a central role in relational 
memory binding (Hannula and Ranganath, 
2008). Its activation has been shown previ-
ously to correlate with the quantity of novel 
and successful mnemonic processing (Stern 
et al., 1996; Brewer et al., 1998; Wagner et al., 
1998; Eldridge et al., 2000; Zeineh et al., 
2000, 2003). During the recall condition of 
the task, THC augmented activation in the 
left medial prefrontal and dorsal anterior 
cingulate cortex (ACC), areas that have been 
related to retrieval monitoring and verifica-
tion (Simons et al., 2005; Fleck et al., 2006). 
THC also attenuated left rostral ACC and 
bilateral striatal activation, and its effect in the 
ventral striatum was directly correlated with 
the severity of psychotic symptoms induced 
by it concurrently, demonstrating that the 
acute induction of psychotic symptoms by 
THC is related to its effects on striatal func-
tion. This study also provided the first human 
evidence that impairments in learning and 
memory induced by cannabis are mediated 
through its effects on medial temporal and 
prefrontal function.
Subsequently,  Bossong et al. (2011) 
reported an attenuation of activity under 
the influence of THC in the insula and 
inferior frontal gyrus on the right side and 
in the middle occipital gyrus on the left 
side during the encoding condition of an 
associative memory task involving pictorial 
stimuli. During the recall condition, THC 
enhanced the engagement of the cuneus and 
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2006). During an auditory processing condi-
tion, THC attenuated activation bilaterally in 
the anterior and posterior superior temporal 
gyrus and middle temporal gyrus, the insu-
lae and in the supramarginal gyri and in the 
right inferior frontal gyrus and left cerebel-
lum relative to the placebo condition. During 
a visual processing condition, THC attenu-
ated activation in the extrastriate visual cor-
tex and enhanced activation in lingual and 
middle occipital gyri (corresponding to the 
primary visual cortex) on the right side and 
parts of the lingual and fusiform gyri extend-
ing anteriorly on the left side.
reward and salience processing
Bhattacharyya et al. (2012c) examined the 
effect of THC on attentional salience pro-
cessing and its relationship with psychotic 
symptoms induced under its influence. 
Employing a visual oddball detection task, 
they observed that relative to placebo THC 
attenuated activation in the right caudate 
but augmented it in the right prefrontal 
cortex, including the inferior frontal gyrus, 
during the processing of “salient” oddball 
stimuli relative to “non-salient” standard 
stimuli. This was associated with a reduc-
tion in response latency to standard relative 
to oddball stimuli under THC, suggesting 
that the non-salient standard stimuli may 
have appeared relatively more salient under 
the influence of THC. This is consistent with 
evidence that insignificant sensory stimuli 
or commonplace conversations acquire new 
meanings and significance under the influ-
ence of cannabis (Tart, 1970). The effect of 
THC in the right caudate was negatively 
correlated with the severity of the psy-
chotic symptoms it induced and its effect 
on response latency. These results provide 
experimental support for the salience model 
of psychosis (Kapur, 2003), are consistent 
with evidence of abnormal salience attribu-
tion in patients with schizophrenia (Jensen 
et al., 2008; Murray et al., 2008) as well as 
linking aberrant salience attribution and 
the presence of psychotic symptoms (Roiser 
et al., 2009). Furthermore, they provide the 
first evidence that the effects of cannabis 
on psychosis may be mediated by influ-
encing the neural substrate of attentional 
salience processing.
van Hell et al. (2012) employed a 
monetary reward task involving reward 
anticipation and feedback conditions to 
(Ramaekers et al., 2009; Crean et al., 2011) 
and reported that administration of THC 
resulted in a decrease in the normal activa-
tion associated with response inhibition in the 
right inferior frontal gyrus as well as the ACC 
– key regions implicated in inhibitory control 
(Garavan et al., 1999; Rubia et al., 2001).
eMotional and sensory 
processing
Several studies have employed neuroimaging 
to study the effects of THC on emotional 
and sensory processing. Phan et al. (2008) 
investigated the effect of a small dose of 
THC during the processing of social signals 
of threat by using angry and fearful faces and 
reported an attenuation of amygdalar activa-
tion. Although this was not associated with 
any changes in anxiety ratings, the authors 
interpreted their results as indicative of a 
potential anxiolytic role of THC. It is likely 
that lack of a significant anxiogenic effect in 
this study was related to the lower dose of 
THC employed by Phan and colleagues as in 
a subsequent study, Fusar-Poli et al. (2009) 
reported a significant increase in anxiety rat-
ings under the influence of a higher dose of 
THC. However, these effects were not associ-
ated with modulation of amygdala activity 
under the influence of THC. Instead, THC 
produced an increase in engagement of the 
right inferior parietal lobule and attenua-
tion of engagement of the left medial fron-
tal gyrus while viewing mildly fearful faces. 
While viewing intensely fearful faces, there 
was an increase in engagement of the left 
precuneus and primary sensorimotor corex 
bilaterally and decrease in engagement of the 
middle frontal gyrus bilaterally and in the 
posterior cingulate gyrus. In a subsequent 
three-way comparison between the effects 
of THC and cannabdiol, a non-psychoactive 
ingredient in cannabis, relative to the placebo 
condition, the same group reported a modu-
latory effect of THC on amygdalar process-
ing (Bhattacharyya et al., 2010), which was 
directly correlated with the increase in anxi-
ety induced by it suggesting that the lack of 
effect on amygdala activation in the former 
study (Fusar-Poli et al., 2009) may have been 
related to a modestly powered sample.
Winton-Brown et al. (2011) examined 
the modulation of activation during audi-
tory and visual processing in healthy sub-
jects as the acute abnormalities in sensory 
processing (Tart, 1970) under the influence 
of cannabis are similar to those experienced 
precuneus. As the authors did not observe 
any significant effect of THC on task perfor-
mance, the neural effects may be interpreted 
as being related to the pharmacological 
effects of the drug rather than being con-
founded by differential task performance.
More recently, Bhattacharyya et al. 
(2012b) employed their previously estab-
lished design (Bhattacharyya et al., 2009b) 
and examined the genetic moderation of the 
neural effects of orally administered THC 
during memory processing. Variations in 
genes modulating central dopaminergic neu-
rotransmission, such as AKT1 (rs1130233) 
and dopamine transporter (DAT1) (40 base-
pair variable number of tandem repeats in 
the 3′ untranslated region) were found to 
modulate the effects of THC on medial 
temporal, striatal, and midbrain function 
during encoding and recall conditions. 
Furthermore, the effects of THC on striatal 
and midbrain activation during the encod-
ing and recall conditions, respectively, of the 
verbal memory task were greater in those 
individuals carrying the risk variants of both 
the genes compared to the rest.
attention and response 
inhibition
O’Leary et al. (2002) examined the neural 
correlates of the attentional deficits reported 
following both acute administration and 
chronic use of cannabis (Hall and Solowij, 
1998; Solowij and Michie, 2007). During a 
dichotic listening task performed by a group 
of regular abstinent cannabis users they 
observed an increase in regional cerebral 
blood flow (rCBF) in the temporal poles 
bilaterally, cerebellum, insula, and putamen 
on the right side and the left ventral frontal 
cortex and a decrease in rCBF in the left supe-
rior temporal gyrus, right occipital lobe and 
bilateral frontal cortical regions areas that 
form an integral component of the atten-
tional network (Berger and Posner, 2000). 
In a subsequent study (O’Leary et al., 2007), 
the authors employed an improved design 
that allowed them to minimize the carryo-
ver effects of THC and reported a significant 
increase in rCBF bilaterally in the anterior 
insula, anterior cingulate, orbital frontal lobe, 
temporal poles, and cerebellum and decrease 
in rCBF in the mesial occipital lobes and pre-
cuneus under the influence of THC.
Borgwardt et al. (2008) examined the 
neural substrates for the impairments in psy-
chomotor control reported in cannabis users 
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main cannabinoid receptor (CB1; Wilson 
and Nicoll, 2002; Eggan and Lewis, 2007) 
and are likely to be mediated through the 
modulation of different neurotransmitter 
systems (Pertwee, 2008a,b). Delineation of 
the precise neural mechanisms underlying 
the distinct and often opposite acute cog-
nitive and symptomatic effects of different 
cannabinoids in man complements existing 
evidence from basic science regarding the 
role of endocannabinoids in cognitive and 
emotional processing. This may not only 
help in modeling different aspects of the 
psychopathology of mental disorders such 
as schizophrenia and offer insights into 
their underlying mechanisms, but may sug-
gest potentially new therapeutic targets for 
drug discovery.
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